ArticleNature communications2022
Construction of emissive ruthenium(II) metallacycle over 1000 nm wavelength for in vivo biomedical applications.
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Counterion modulation of aza-BODIPY aggregation behaviour for boosted sonodynamic therapy.Chemical science · 2026Article
- Endogenous Albumin-Mediated Disassembly of Phthalocyanine Nanoparticles for Tumor-Selective Imaging and Sonodynamic Therapy.Chemical & biomedical imaging · 2026Article
- Revisiting small-molecule fluorescent probes in food freshness detection.Smart molecules : open access · 2026Review
- Folate-Targeted Liposomal Delivery of a Ru(II)-Based Photosensitizer for Photodynamic Tumor Therapy via Pyroptosis Induction.Advanced healthcare materials · 2026Article
- Architecting NIR-II metal supramolecular dyes-illuminating the path to precision medicine.Chemical science · 2026Review
- Fabrication of docetaxel-loaded PEG-modified calcium carbonate-loaded zeolite imidazole nanoframeworks for synergic gastric cancer photothermal therapy.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Micelle-Encapsulated Theranostic Phthalocyanine and Naphthalocyanine Derivatives for Photothermal Therapy and Photoacoustic Imaging with NIR-I vs NIR-II Irradiation.ACS applied nano materials · 2025Article
- Tandem reaction-powered near-infrared fluorescent molecular reporter for real-time imaging of lung diseases.Chemical science · 2025Article
- Simply Designed and Universal DNA Nanohydrogel for Stimuli-Responsive NIR-II Fluorescence Imaging of Early-Stage Tumor.Analytical chemistry · 2025Article
- A Review on Perception of Binding Kinetics in Affinity Biosensors: Challenges and Opportunities.ACS omega · 2025Review
- A review of combined imaging and therapeutic applications based on MNMs.Frontiers in chemistry · 2025Review
- Photochemical and biological dual-effects enhance the inhibition of photosensitizers for tumour growth.Chemical science · 2024Article
- Supramolecular coordination platinum metallacycle-based multilevel wound dressing for bacteria sensing and wound healing.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- Synthesis, supramolecular aggregation, and NIR-II phosphorescence of isocyanorhodium(i) zwitterions.Chemical science · 2023Article
- Receptor-Targeted Carbon Nanodot Delivery through Polymer Caging and Click Chemistry-Supported LRP1 Ligand Attachment.Polymers · 2023Article
- High-Performance Hybrid Phototheranostics for NIR-IIb Fluorescence Imaging and NIR-II-Excitable Photothermal Therapy.Pharmaceutics · 2023Article
- A copper-seamed coordination nanocapsule as a semiconductor photocatalyst for molecular oxygen activation.Chemical science · 2023Article
- In situ orderly self-assembly strategy affording NIR-II-J-aggregates for in vivo imaging and surgical navigation.Nature communications · 2023Article
- Acceptor engineering of metallacycles with high phototoxicity indices for safe and effective photodynamic therapy.Chemical science · 2023Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although Ru(II)-based agents are expected to be promising candidates for substituting Pt-drug, their in vivo biomedical applications are still limited by the short excitation/emission wavelengths and unsatisfactory therapeutic efficiency. Herein, we rationally design a Ru(II) metallacycle with excitation at 808 nm and emission over 1000 nm, namely Ru1085, which holds deep optical penetration (up to 6 mm) and enhanced chemo-phototherapy activity. In vitro studies indicate that Ru1085 exhibits prominent cell uptake and desirable anticancer capability against various cancer cell lines, especially for cisplatin-resistant A549 cells. Further studies reveal Ru1085 induces mitochondria-mediated apoptosis along with S and G2/M phase cell cycle arrest. Finally, Ru1085 shows precise NIR-II fluorescence imaging guided and long-term monitored chemo-phototherapy against A549 tumor with minimal side effects. We envision that the design of long-wavelength emissive metallacycle will offer emerging opportunities of metal-based agents for in vivo biomedical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.